On May 22, Kelun-Biotech Biopharmaceutical rose 7.58% in regular trading, trading at 478.0 HKD/share, with trading volume of approximately 153 million HKD.

On the news front, the company announced it will present multiple clinical research results at the ASCO Annual Meeting, with its core TROP2 ADC sacituzumab tirumotecan (sac-TMT) and RET inhibitor lenboretinib fumarate both selected for oral presentations in the metastatic non-small cell lung cancer session. Data showed that sac-TMT combined with pembrolizumab for first-line treatment of PD-L1 positive advanced NSCLC achieved its primary endpoint in a Phase III trial, significantly extending progression-free survival versus monotherapy, with objective response rate reaching 70.2% and a manageable overall safety profile consistent with the known profiles of individual components.

Additionally, the company's earlier collaboration with Merck on sac-TMT in the Phase III TroFuse-005 study for advanced or recurrent endometrial cancer successfully met dual primary endpoints of overall survival and progression-free survival, marking a series of global Phase III clinical victories that continue to catalyze share price performance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)